Skip to main content

Table 1 Clinical characteristics of patients with rheumatoid arthritis in a nationwide database

From: Comparison of developing tuberculosis following tumor necrosis factor inhibition and interleukin-6 inhibition in patients with rheumatoid arthritis: a nationwide observational study in South Korea, 2013–2018

  

Anti-TNF

 

All

(n = 4736)

ETA

(n = 934)

INF

(n = 561)

ADA

(n = 1218)

GOL

(n = 858)

TOC

(n = 1165)

P value

Age (years), mean ± SD

54.2 ± 13.3

53.4 ± 14.3

56.2 ± 12.7

52.3 ± 13.6

55.0 ± 12.8

55.5 ± 12.6

 < 0.0001

Women, n (%)

3841 (81.1)

747 (80.0)

471 (84.0)

947 (77.8)

708 (82.5)

968 (83.1)

0.0021

Combination of DMARDs, n (%)a

 Methotrexate

3953 (83.5)

768 (82.2)

485 (86.5)

1047 (86.0)

772 (90.0)

881 (75.6)

 < 0.0001

 Leflunomide

678 (14.3)

89 (9.5)

144 (25.7)

169 (13.9)

73 (8.5)

203 (17.4)

 < 0.0001

 Tacrolimus

212 (4.5)

36 (3.9)

15 (2.7)

49 (4.0)

33 (3.9)

79 (6.8)

0.0003

Glucocorticoid use, n (%)a

4143 (87.5)

817 (87.5)

486 (86.6)

1081 (88.8)

672 (78.3)

1087 (93.3)

 < 0.0001

LTBI prophylaxis, n (%)

1168 (24.7)

279 (29.9)

113 (20.1)

298 (24.5)

182 (21.2)

296 (25.4)

 < 0.0001

Entry year, n (%)

      

 < 0.0001

 2013

85 (1.8)

16 (1.7)

18 (3.2)

14 (1.2)

11 (1.3)

26 (2.2)

 

 2014

1208 (25.5)

321 (34.4)

187 (33.3)

271 (22.3)

182 (21.2)

247 (21.2)

 

 2015

956 (20.2)

181 (19.4)

127 (22.6)

225 (18.5)

179 (20.9)

244 (20.9)

 

 2016

1002 (21.2)

164 (17.6)

100 (17.8)

291 (23.9)

174 (20.3)

273 (23.4)

 

 2017

1033 (21.8)

163 (17.5)

89 (15.9)

276 (22.7)

222 (25.9)

283 (24.3)

 

 2018

452 (9.5)

89 (9.5)

40 (7.1)

141 (11.6)

90 (10.5)

92 (7.9)

 
  1. TNF tumor necrosis factor, ETA etanercept, INF infliximab, ADA adalimumab, GOL golimumab, TOC tocilizumab, SD standard deviation, DMARDs disease-modifying anti-rheumatic drugs, LTBI latent tuberculosis infection
  2. aThe use of conventional DMARDs and glucocorticoid was evaluated during 3 months after initiating biologic drugs